Paroxetine with pindolol augmentation: a double-blind, randomized, placebo-controlled study in depressed in-patients. |
| |
| Authors: | Christian Geretsegger Waltraud Bitterlich Renate Stelzig Christoph Stuppaeck Brigitta Bondy Wolfgang Aichhorn |
| |
| Institution: | University Clinics of Psychiatry and Psychotherapy I, Paracelsus Medical University, Ignaz-Harrer-Str. 79, 5020 Salzburg, Austria. c.geretsegger@salk.at |
| |
| Abstract: | Pindolol, a 5-HT1A autoreceptor antagonist, given in combination with selective serotonin reuptake inhibitors (SSRIs), may enhance and/or accelerate the therapeutic efficacy of SSRIs. Fifty patients, meeting ICD-10 criteria for major depressive disorder or bipolar depression, were enrolled in our randomized, placebo-controlled, double-blind trial. One group received paroxetine plus pindolol (2.5 mg t.i.d.), and the other group received paroxetine plus placebo. The proportion of patients with sustained response (>or=50% reduction of baseline HAM-D 17 score maintained until the endpoint; p=0.252) and the proportion of patients with remission (HAM-D 17
|
| |
| Keywords: | |
|
|
